NCT01339988Unknown4 期
Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 10
- 主要终点
- Overall survival
研究概览
简要总结
Long-term follow-up studies have demonstrated significant late toxicities of total body irradiation (TBI), which are most marked in children radiated at a young age. Growth failure, decline in cognitive function, and endocrine abnormalities have all been described. Good outcomes can be achieved with alkylating agents only as a preparative regimen. This plan will use a combination of busulfan and cyclophosphamide (Bu/Cy) with or without antithymocyte globulin (ATG) to reduce the late toxicities of therapy that includes TBI.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 21 Years（Child, Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Suitable cord blood from matched unrelated or related donor.
- •Cardiac (Echo/EKG): shortening fraction ≥ 27%
- •Electrolytes within normal CCHMC limits.
- •Pulmonary function tests: DLCO ≥ 50%
- •Renal: creatinine clearance/GFR ≥ 60 ml/minute/1.73m2
- •Lumbar puncture: no leukemic infiltrate.
- •CBC: ANC ≥ 1000ml and unsupported platelet count of ≥ 50,000/ml
- •Documented HSV and CMV titers, Hepatitis B surface antigen, Hepatitis C by serology, HIV by serology: all negative.
- •Hepatic transaminases < 2.5x normal; Total bilirubin < 2 mg/dl Patients who do not meet above organ function criteria (liver, cardiac, renal), due to the presence of a tumor compromising these organs, may have exception made for these criteria and remain eligible for treatment plan after consultation with Program Director of Blood and Marrow Transplant
排除标准
- •Patients with neoplastic or non-neoplastic disease of any major organ system that would compromise their ability to withstand the pre-transplant conditioning regimen.
- •Patients with uncontrolled (culture or biopsy positive) infections requiring intravenous antivirals, antibiotics, or antifungals. Patients on prolonged antifungal therapy with a history of fungal infection should be considered for a non-myeloablative protocol.
- •Patients who are pregnant or lactating. Patients of childbearing potential must practice an effective method of birth control while participating on this treatment plan.
- •HIV seropositive patients
研究组 & 干预措施
Busulfan/Cyclophosphamide
Experimental
干预措施: Busulfan/Cyclophosphamide (Drug)
结局指标
主要结局
Overall survival
时间窗: Five years
次要结局
- Disease free survival(Five years)
研究者
相似试验
招募中
不适用
TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological DiseasesHematopoietic Stem Cell TransplantationMalignant Hematological DiseasesNCT05929092The First Affiliated Hospital of Soochow University40
招募中
不适用
Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal CarcinomaIntensity-Modulated RadiotherapyNasopharyngeal CarcinomaNCT05994170Zhongshan People's Hospital, Guangdong, China454
暂停
2 期
ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDSMyelodysplastic SyndromeAcute LeukemiaNCT01709396Ottawa Hospital Research Institute20
已完成
1 期
Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune DisordersSystemic Lupus ErythematosusAutoimmune DiseasesSystemic SclerosisDermatomyositisJuvenile Rheumatoid ArthritisNCT00010335Fred Hutchinson Cancer Center6
终止
1 期
Image Guided Reirradiation of High-grade GliomaMalignant GliomaGlioblastomaNCT02025231Rigshospitalet, Denmark31